KMT2AR
Clinical trials for KMT2AR explained in plain language.
Never miss a new study
Get alerted when new KMT2AR trials appear
Sign up with your email to follow new studies for KMT2AR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough leukemia: experimental combo enters human testing
Disease control Recruiting nowThis early-stage study tests the safety of a new drug called ziftomenib when combined with standard chemotherapy for people whose acute myeloid leukemia (AML) has returned or not responded to treatment. The study includes adults with specific genetic changes (NPM1 mutation or KMT…
Matched conditions: KMT2AR
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 17, 2026 03:08 UTC
-
New drug combo shows promise for Hard-to-Treat leukemia
Disease control Recruiting nowThis early-stage study tests whether adding the experimental drug ziftomenib to standard AML treatments is safe and effective. About 420 adults with specific genetic mutations (NPM1 or KMT2A) will receive one of three drug combinations. The goal is to find the best dose and see i…
Matched conditions: KMT2AR
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC